CJC-1295 vs. Ipamorelin: Two Pathways in Growth Hormone Research

CJC-1295 and ipamorelin are two of the most-studied growth-hormone research peptides, and the key to comparing them is that they act on completely different receptors. CJC-1295 is a GHRH analog — it mimics growth-hormone-releasing hormone and acts on the GHRH receptor. Ipamorelin is a GHRP (growth-hormone-releasing peptide) that acts on the ghrelin/GHS receptor. Because the two pathways are separate but complementary, researchers frequently study them together — the combination produces a larger growth-hormone pulse in research models than either produces alone.

Here's how they line up, where they differ, and why they're so often paired.

Two Different Doors to the Same Room

Both peptides are studied for their association with the body's own growth-hormone release — but they knock on different doors to get there.

• CJC-1295 (GHRH analog): mimics GHRH and activates the GHRH receptor on the pituitary. Studied for stimulating endogenous growth-hormone release, working "upstream."
• Ipamorelin (GHRP): activates the ghrelin/GHS receptor, a separate pathway. Studied as a selective secretagogue noted in research for minimal effect on cortisol or prolactin.

Same general research area (endogenous GH), two distinct mechanisms.

Side-by-Side

• Receptor: CJC-1295 → GHRH receptor · Ipamorelin → ghrelin/GHS receptor
• Class: CJC-1295 → GHRH analog · Ipamorelin → GHRP / secretagogue
• Research note: CJC-1295 studied for sustained GHRH-type signaling · Ipamorelin studied for selective, "clean" secretagogue action
• Duration: the DAC version of CJC-1295 is studied for an extended action window; ipamorelin is studied as shorter-acting
• Often studied: together, for a synergistic pulse

Why They're Studied Together

This is the crux of the comparison. Because GHRH-pathway and ghrelin-pathway stimulation are independent, activating both at once is studied for an additive — sometimes described as synergistic — growth-hormone pulse that's larger than either pathway alone. That complementary design is why the two names appear side by side so often in the literature and why researchers evaluate them as a pair, not just as competitors.

Handling Both in the Lab

Both arrive lyophilized and are reconstituted with bacteriostatic water. Store dry powder cold (long-term at -4°F), keep reconstituted vials refrigerated at 36–46°F, minimize freeze-thaw cycles, and verify each by its lot-matched COA.

Frequently Asked Questions

What's the main difference between CJC-1295 and ipamorelin?

They act on different receptors. CJC-1295 is a GHRH analog that works on the GHRH receptor; ipamorelin is a GHRP that works on the ghrelin/GHS receptor. Both are studied in growth-hormone research, but through separate, complementary pathways.

Why are CJC-1295 and ipamorelin often studied together?

Because their pathways are independent. Stimulating the GHRH receptor and the ghrelin receptor at the same time is studied for an additive, synergistic growth-hormone pulse in research models that's larger than either compound produces alone.

Is ipamorelin a GHRH analog like CJC-1295?

No. Ipamorelin is a GHRP (growth-hormone-releasing peptide) that acts on the ghrelin/GHS receptor. CJC-1295 is the GHRH analog. That receptor difference is the whole basis of the comparison.

What is CJC-1295 with DAC versus without?

DAC (Drug Affinity Complex) is a modification studied for extending the compound's action window by slowing clearance. The no-DAC version is studied as shorter-acting. Both remain GHRH-analog research compounds.

How are these peptides stored?

Both ship lyophilized and reconstitute with bacteriostatic water. Keep dry powder cold (long-term -4°F), refrigerate reconstituted vials at 36–46°F, and minimize freeze-thaw cycles. This is storage guidance for research supplies, not medical advice.